Entheon Biomedical Corp. Acquires Lobo Genetics Inc.

Entheon生物医学公司收购Lobo Genetics公司。

2021-07-31 01:00:10 CFN Media Group


  Vancouver, British Columbia–(Newsfile Corp. – July 30, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“) is pleased to announce that the Company completed its acquisition of Lobo Genetics Inc. (“Lobo“), a personalized genetics company with a direct-to-consumer platform currently being used in both the psychedelics and cannabis spaces to provide personalized insights into an individual’s response to hallucinogenic and psychoactive drugs.   Further to the Company’s news release dated June 16, 2021 (the “Initial News Release“), Entheon closed the amalgamation agreement dated June 15, 2021 (the “Agreement“) with Lobo and 13089363 Canada Inc. (“Subco“), a wholly-owned subsidiary of Entheon, whereby Subco and Lobo amalgamated by way of a “three-cornered” amalgamation in accordance with the Canada Business Corporations Act to form one corporation, continuing under the name “Lobo Genetics Inc.”, as a wholly owned subsidiary of the Company (the “Transaction“).   The Transaction Pursuant to the Agreement, the Company issued an aggregate of 5,000,000 common shares in the capital of the Company (the “Consideration Shares“) to the former Lobo shareholders. In addition, Entheon issued an aggregate of 9,603 incentive stock options (the “Replacement Options“) to the holders of the outstanding stock options of Lobo (the “Lobo Stock Options“) in exchange for the cancellation of the Lobo Stock Options, and all outstanding common share purchase warrants in the capital of the Lobo were cancelled. For more information about the Consideration Shares and the Replacement Options, please see the Initial News Release.   The Company also entered into an advisory agreement with John Lem, founder and former Chief Executive Officer of Lobo, to serve as a strategic advisor of industry affairs on Entheon’s advisory board. In connection with his appointment, the Company granted to Mr. Lem an aggregate of 200,000 stock options, in accordance with the terms and conditions of the Company’s stock option plan and the policies of the Canadian Securities Exchange (“CSE“). Each stock option is exercisable for one common share of the Company for a period of 5 years from the grant date at an exercise price of $0.33, based on the closing price of the Company’s shares on July 28, 2021, with 25% of the stock options vesting every 6 months from the date of grant. Mr. Lem will continue to advise and assist with the operations and strategic direction of Lobo Genetics Inc. and HaluGen Life Sciences Inc.   “We are thrilled that the transaction with Lobo has successfully completed, and we very much look forward to working with the Lobo team toward our combined mission of researching a genetic-driven approach to developing personalized psychedelic-assisted psychotherapeutic (PAP) protocols to treat substance use disorders,” said Chief Executive Officer of Entheon, Timothy Ko. “With the acquisition of Lobo comes the addition of key staff members and enhanced expertise in the field of genetics. With increased capacity to screen patients, on a genetic basis, for underlying psychiatric disorders prior to undertaking PAP, Entheon is furthering its commitment toward safety and predictability in psychedelic therapies while aggregating data that can be used to determine which psychedelic molecules are best-suited for a particular patient.”   Mr. Lem commented, “Lobo is pleased to officially join the Entheon team. We are excited to continue to leverage our technology platform to help personalize the psychedelics experience through genetic testing and data-driven insights.”   Lobo Genetics Inc. Lobo is a Toronto-based personalized genetics company with a direct-to-consumer (DTC) platform currently being used in both the psychedelics and cannabis spaces to provide personalized insights into an individual’s response to hallucinogenic and psychoactive drugs.   About Entheon Biomedical Corp. Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (“DMT Products“) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.   For more information, please contact the Company at: Entheon Biomedical Corp. Joseph Cullen, Investor Relations Telephone: +1 (778) 919-8615 [email protected] https://entheonbiomedical.com/   For media inquiries, please contact Crystal Quast at: Bullseye Corporate Crystal Quast Telephone: +1 (647) 529-6364 [email protected]   Cautionary Note on Forward-Looking Information This news release includes certain forward-looking statements and forward-looking information (collectively, “forward-looking statements“) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein including, without limitation, the anticipated business plans and expectations of the Company, are forward-looking statements. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Often, but not always, forward-looking information can be identified by words such as “pro forma”, “plans”, “expects”, “will”, “may”, “should”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “potential” or variations of such words including negative variations thereof, and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and other factors include, among others, the Company being able to follow through with anticipated business plans and expectations of the Company, the ability of the Company to obtain sufficient financing to fund its business activities and plans, delays in obtaining regulatory approvals (including of the Canadian Securities Exchange), changes in laws, regulations and policies affecting the Company’s operations and the Company’s limited operating history.   Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update any of the forward-looking statements in this presentation or incorporated by reference herein, except as otherwise required by law.   The CSE has not approved nor disapproved the contents of this news release. This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
不列颠哥伦比亚省温哥华-(Newsfile Corp.-2021年7月30日)-Entheon Biomedical Corp.(CSE:ENBI)(OTCQB:ENTBF)(FSE:1XU1)(“Entheon”或“本公司”)高兴地宣布,本公司完成了对Lobo Genetics Inc.(“Lobo”)的收购,该公司是一家个性化基因公司,拥有一个直接面向消费者的平台,目前用于迷幻药和大麻领域,为个人对致幻和精神活性药物的反应提供个性化见解。 继本公司日期为2021年6月16日的新闻稿(“初步新闻稿”)之后,Etheon与Lobo及Entheon的全资附属公司13089363 Canada Inc.(“Subco”)签署日期为2021年6月15日的合并协议(“协议”),据此,Subco及Lobo根据加拿大商业公司法以“三方”合并的方式合并成立一间公司,继续以“Lobo Genetics Inc.”的名称作为本公司的全资附属公司(“交易”)。 交易 根据协议,本公司向前Lobo股东发行本公司资本中合共5,000,000股普通股(“代价股份”)。此外,Entheon向Lobo尚未行使的股票期权(“Lobo股票期权”)持有人发行合共9,603份激励股票期权(“替换期权”),以换取取消Lobo股票期权,而Lobo资本中所有尚未行使的普通股购买权证已被取消。有关代价股份及替代选择的更多资料,请参阅初步新闻稿。 该公司还与Lobo的创始人和前首席执行官约翰·莱姆(John Lem)达成了一项顾问协议,担任Entheon顾问委员会的行业事务战略顾问。就其委任而言,本公司根据本公司股票期权计划的条款及条件及加拿大证券交易所(“CSE”)的政策,向Lem先生授予合共200,000份股票期权。每份股票期权可就一股本公司普通股行使,行使期为自授出日期起计5年,行使价为0.33美元,以本公司股份于2021年7月28日收盘价为基础,由授出日期起计每6个月授予25%的股票期权。Lem先生将继续为Lobo Genetics Inc.和HaluGen Life Sciences Inc.的运营和战略方向提供建议和协助。 Entheon首席执行官Timothy Ko说:“我们很高兴与Lobo的交易成功完成,我们非常期待与Lobo团队合作,共同完成我们的使命,即研究一种基因驱动的方法,开发个性化迷幻辅助精神治疗(PAP)协议,以治疗药物使用障碍。”“收购Lobo后,增加了关键员工,并增强了遗传学领域的专业知识。随着在进行PAP之前在遗传基础上筛查患者潜在精神疾病的能力的增强,Entheon正在进一步致力于迷幻治疗的安全性和可预测性,同时收集数据,用于确定哪些迷幻分子最适合特定患者。“ Lem先生评论道:“Lobo很高兴正式加入Entheon团队。我们很高兴继续利用我们的技术平台,通过基因测试和数据驱动的洞察来帮助个性化迷幻体验。“ 洛博遗传学公司。 Lobo是一家总部位于多伦多的个性化遗传学公司,其直接面向消费者(DTC)平台目前正在迷幻药和大麻领域使用,以提供个性化的见解,了解个人对致幻和精神活性药物的反应。 关于Entheon生物医学公司。 Entheon是一家生物技术研究和开发公司,致力于开发和商业化一系列安全有效的基于二甲基色胺的迷幻治疗产品(“DMT产品”),用于治疗成瘾和药物使用障碍。在获得所有必要的监管批准和许可的前提下,Entheon打算通过向美国、欧洲联盟某些国家和整个加拿大的医生、诊所和有执照的精神病医生销售其DMT产品来创收。 如欲查询更多资料,请联络本公司: 恩席恩生物医学公司。 约瑟夫·卡伦,投资者关系 电话:+1(778)919-8615 [电子邮件受保护] https://entheonbiomedical.com/ 如有传媒查询,请联络Crystal Quast: 靶心公司 晶体Quast 电话:+1(647)529-6364 [电子邮件受保护] 关于前瞻性信息的警示说明 本新闻稿包括适用的加拿大证券立法含义内的某些前瞻性陈述和前瞻性信息(统称为“前瞻性陈述”)。所有陈述,除历史事实陈述外,包括但不限于公司的预期业务计划和预期,均为前瞻性陈述。虽然本公司相信该等陈述是合理的,但不能保证该等预期将被证明是正确的。通常,但并非总是,前瞻性信息可以通过诸如“形式”、“计划”、“预期”、“将会”、“可能”、“应该”、“预算”、“预定”、“估计”、“预测”、“打算”、“预期”、“相信”、“潜在”等词或这些词的变体,包括其负面变体,以及指可能、可能、将要、可能或将要发生或采取或实现的某些行动、事件或结果的短语来识别。前瞻性陈述涉及已知和未知的风险、不确定性和其他因素,这些因素可能导致本公司的实际结果、业绩或成就与前瞻性陈述所表达或暗示的任何未来结果、业绩或成就存在重大差异。该等风险及其他因素包括,除其他外,本公司能否贯彻执行预期业务计划及对本公司的期望、本公司获得足够融资以资助其业务活动及计划的能力、在获得监管批准(包括加拿大证券交易所)方面的延迟、影响本公司业务的法律、法规及政策的变化以及本公司有限的经营历史。 告诫读者不要过分依赖前瞻性陈述。除法律另有要求外,本公司不承担更新本陈述中或在此引用的任何前瞻性陈述的义务。 CSE既没有批准也没有不批准本新闻稿的内容。 本文由CFN Enterprises Inc.(OTCQB:CNFN)发表,该公司是CFN Media的所有者和运营商,CFN Media是行业领先的机构和数字金融媒体网络,致力于新兴的CBD和合法大麻行业。请致电+1(833)420-CNFN了解更多信息。